B+
Bull case
0%
Probability
Target price
$12.00
+89.9% vs current
DTIL
Precision BioSciencesANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
1%
Probability
Target price
$7.80
+23.4% vs current
B-
Bear case
0%
Probability
Target price
$4.50
-28.8% vs current
AI sentiment snapshot
Latest data as of 2026-05-16
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+75.0
Score
AI commentary
This remains a cautious post-earnings follow-up. Despite the queue metadata citing May 13, 2026, the company's primary-source earnings release and 8-K were filed on May 5, 2026 [#8-K-2026-05-05]. The immediate price reaction was mixed: DTIL closed at 7.45 on May 5 versus 7.63 on May 4, then recovered to 8.20 by May 12, so the market appears to have absorbed the earnings print as supportive on runway but still dependent on upcoming clinical evidence. Headline flow has been active and mostly company-generated, confirmed post-print analyst target/rating revisions remain limited or unavailable, and even closer gene-editing peers are only partial comparators, which keeps conviction capped.
RankAlpha Sentiment Codex - 2026-05-16
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-30eventEASL 2026 PBGENE-HBV poster is the clearest near-term value inflectionHigh impact
Management said a late-breaking EASL Congress 2026 poster will present first evidence of elimination and inactivation of cccDNA in liver biopsies from PBGENE-HBV-treated chronic hepatitis B patients. Because DTIL remains an early clinical gene-editing story, investor reaction will likely depend more on biopsy/biomarker credibility and safety interpretation than on the Q1 financial print itself [#10-Q-2026-05-05].
2026-06-30catalystPost-Q1 earnings digestion centers on runway durability and execution proof pointsHigh impact
On May 5, 2026, Precision reported Q1 revenue of $10.8 million, cash/cash equivalents/restricted cash of $125.8 million, and said existing cash plus operating discipline and ATM availability should fund operations and PBGENE-HBV/PBGENE-DMD data milestones through 2028. The same update also pushed PBGENE-HBV cumulative exposure to 16 patients and 38 administrations across five cohorts. That helps near-term financing anxiety, but the setup still needs clinical follow-through to sustain sentiment [#8-K-2026-05-05] [#10-Q-2026-05-05].
2026-12-31catalystFUNCTION-DMD first multi-patient human data remains the major longer-horizon swing factorHigh impact
Precision had activated Arkansas Children's Hospital as its first FUNCTION-DMD site and was actively enrolling patients as of the May 5 business update, while the 2025 10-K said initial data from multiple patients are expected by year-end 2026 with safety and early efficacy assessed by near full-length dystrophin expression from muscle biopsies. This is the clearest distinct long-horizon program catalyst, but also the highest binary execution risk in the story [#10-Q-2026-05-05] [#10-K-2026-03-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-16 • Updated nightlySource: Internal modelMethodology